I have a hunch that today is close to being a “local summit” for the share price. The Ratiopharm deal does nothing to remove the threat from the Copaxone patent case that, surprisingly, has been dismissed as a sideshow by almost everyone on Wall Street.
Teva is inarguably a major beneficiary of The Global Demographic Tailwind, and the stock will presumably do well in the long term. What I’m not so sure about is the stock’s performance during the next year or so.
Market Data 
Markets 
AI
